Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -608.4%
Net margin was -608.4% in Q1 FY2026, down 291.9 pp from a year earlier. On a trailing-twelve-month basis it was -266.9%, up 75.4 pp year over year. Over 3 fiscal years it widened by 325.9 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 4 analysts of -28.1% for the fiscal year ending Dec 2026, up from -240.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -608.4%-374.1 pp QoQ
- Last fiscal yearDec 2025
- -240.3%+142.9 pp YoY
- LTMMar 2026
- -266.9%+75.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -240.3%
- Year-over-year change
- +142.9pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -240.3% | +142.9pp |
| FY2024 | 2024-12-31 | -383.2% | -95.1pp |
| FY2023 | 2023-12-31 | -288.2% | +278.1pp |
| FY2022 | 2022-12-31 | -566.3% | +7115.3pp |
| FY2021 | 2021-12-31 | -7681.6% | — |
Net Margin vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 net margin of -266.9% is the 5th highest of the 8 companies compared; the peer median is -173.5%.
- Its year-over-year change of +75.4 pp is the 2nd highest of 7, against a peer median of -105.5 pp.
- Over three fiscal years its change of +325.9 pp compares with a peer median of -103.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -9.0% | +115.2 pp | — | |
| LTM Mar 2026 | -89.6% | +60.0 pp | +16.0 pp | |
| LTM Mar 2026 | -110.0% | -88.0 pp | -104.5 pp | |
| LTM Mar 2026 | -173.5% | -123.0 pp | -102.4 pp | |
| LTM Mar 2026 | -266.9% | +75.4 pp | +325.9 pp | |
| LTM Mar 2026 | -589.8% | — | — | |
| LTM Mar 2026 | -2895.1% | -2909.4 pp | — | |
| LTM Mar 2026 | -4840.8% | -3838.0 pp | -1239.0 pp | |
SGMTSagimet Biosciences Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
ZURAZura Bio Limited | FY2025 | — | — | — |
| Peer median (excluding FHTX) | -173.5% | -105.5 pp | -103.4 pp | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.32M | 19.23M | 34.16M | 22.6M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.33M |
| Gross Profit | 1.32M | 19.23M | 34.16M | 22.6M | 27.58M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 89.2% |
| Research & Development | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
| Selling, General & Admin | 21.73M | 30.75M | 32.37M | 28.36M | 27.55M |
| Operating Expenses | 102.05M | 136.37M | 142.06M | 125.29M | 109.68M |
| Depreciation & Amortization | 3.23M | 3.32M | 3.45M | 3.12M | 3.33M |
| EBITDA | (96.19M) | (105.56M) | (90.75M) | (97.17M) | (70.95M) |
| EBITDA Margin | -7292.4% | -549.0% | -265.7% | -429.9% | -229.5% |
| Operating Income | (100.73M) | (117.14M) | (107.91M) | (102.68M) | (82.11M) |
| Operating Margin | -7637.1% | -609.2% | -315.9% | -454.3% | -265.6% |
| Interest Income | 59K | 5.68M | 10.88M | 11.9M | 8.75M |
| Interest Expense | 1.91M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (586K) | 8.26M | 13.71M | 16.06M | 7.82M |
| Income Before Tax | (101.32M) | (108.88M) | (94.2M) | (86.62M) | (74.28M) |
| Pre-Tax Margin | -7681.6% | -566.3% | -275.8% | -383.2% | -240.3% |
| Income Tax Expense | 0 | 0 | 4.23M | 0 | 0 |
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Net Margin | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (Basic) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| EPS (Diluted) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| Weighted Avg Shares | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Weighted Avg Shares (Diluted) | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.